Get to know our clinical trials
Trial of elranatamab in participants with newly diagnosed multiple myeloma not suitable for transplantation
- PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED, TWO-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) DARATUMUMAB LENALIDOMIDE COMPARED TO DARATUMUMUMAB LENALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR TRANSPLANTATION. IMMUNOTHERAPY
- Code EudraCT: 2021-000803-20
- Protocol number: C1071006
- Promoter: Pfizer
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.